Predict your next investment

Holding Company
kinled.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

About Kinled Holding

Kinled Holding has an active management team that constantly reviews potential business investments in the luxury, engineering, real estate, and medical device sector. The company manages funds exclusively for the benefit of a private Family Office.

Kinled Holding Headquarter Location

Room 902, Wilson House 19-27 Wyndham Street

Hong Kong

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kinled Holding News

System1 Raises $25M in Series A Funding

Sep 12, 2018

System1 Biosciences, Inc. , a San Francisco, CA-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for neurological and psychiatric disorders, completed a $25m Series A financing. The round was co-led by CRV and Pfizer Ventures with participation from Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb Investment Network, Liquid 2 Ventures, and Boom Capital. The company will use the new capital to drive its drug discovery programs for epilepsy, autism, and schizophrenia. Co-founded by assistant professor of psychiatry at Columbia University Sean Escola, M.D., Ph.D., CEO, and Saul Kato, Ph.D., assistant professor of neurology at the University of California, San Francisco, System1 uses stem cell lines derived from patients with brain disease, to produce cerebral organoids, which are three-dimensional in vitro systems that allow researchers to identify potential drug compounds that are more likely to be clinically efficacious compared to those found using standard methods. The company uses robotic automation to develop its organoids, permitting the collection of a massively scaled, high-content dataset across multiple modes of biological measurement over many months and under many conditions. Advanced data analysis applied to the resulting data streams yield systems-level characterizations of disease never before achievable. These characterizations, or “deep phenotypes,” are exploited to identify novel therapeutic targets and drug treatments for complex neurological and psychiatric diseases. In addition to existing directors Dr. Escola, Dr. Kato and Frederic Kerrest, COO and co-founder of the enterprise identity software company Okta, System1 added George Zachary, of CRV, and Margi McLoughlin, Ph.D., of Pfizer, as new members of its board of directors, and Dylan Morris, of CRV, and Laszlo Kiss, Ph.D., of Pfizer, as new board observers. FinSMEs 12/09/2018

Kinled Holding Investments

6 Investments

Kinled Holding has made 6 investments. Their latest investment was in PreComb Therapeutics as part of their Seed VC on April 4, 2021.

CBI Logo

Kinled Holding Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/26/2021

Seed VC

PreComb Therapeutics

$2.41M

Yes

FiveT, High-Tech Grunderfonds, and Undisclosed Investors

2

11/5/2019

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

9/12/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/4/2017

Series D

Subscribe to see more

$99M

Subscribe to see more

10

10/25/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/26/2021

11/5/2019

9/12/2018

10/4/2017

10/25/2016

Round

Seed VC

Convertible Note

Series A

Series D

Series B

Company

PreComb Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.41M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

FiveT, High-Tech Grunderfonds, and Undisclosed Investors

Sources

2

10

10

10

10

Kinled Holding Portfolio Exits

1 Portfolio Exit

Kinled Holding has 1 portfolio exit. Their latest portfolio exit was KB Medical on August 02, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/2/2017

Acquired

4

Date

8/2/2017

Exit

Acquired

Companies

Valuation

Acquirer

Sources

4

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.